Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy (PEM-PRO) in High-risk Prostate Cancer Patients

NCT04565496 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

NCT NCT04565496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04565496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy (PEM-PRO) in High-risk Prostate Cancer Patients
Lead sponsor
IRCCS San Raffaele
Phase
Phase 2
Overall status
Withdrawn
Start date
April 10, 2023
Completion date
January 1, 2025
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer